Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/1999
11/09/1999US5981588 Administering to a patient an omega 9-unsaturated fatty acid having at least two double bonds in an amount effective for preventing or alleviating medical symptoms caused by delayed allergy reaction
11/09/1999US5981583 For use in the treatment of pathological conditions such as toxic shock, acute inflammatory conditions, acute phase response, atherosclerosis and cancer
11/09/1999US5981559 Azole derivative with leukotriene (LTs) antagonizing activity and thromboxane (TX) A2 antagonizing activity
11/09/1999US5981540 Selective delta opioid agonists and antagonists; useful as analgesics and in treating general neurologic disorders
11/09/1999US5981535 Substituted xanthines and their use in the treatment of cerebrovascular disorders and other diseases
11/09/1999US5981525 Indole derivatives useful in the treatment of osteoporosis
11/09/1999US5981517 Androstene derivatives
11/09/1999US5981512 Means for treating radiation injuries
11/09/1999US5981511 Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
11/09/1999US5981491 Peptides; metalloenzymes; tumor necrosis factor
11/09/1999US5981490 Peptidyl compounds
11/09/1999US5981483 Compositions comprising modulators of cytokines of the TGF-β superfamily
11/09/1999US5981479 Administering to the aids patient a nonimmunosuppressive, cyclophilin-bining cyclosporin which binds to human genetic engineered cyclophilin and has an activity in the mixed lymphocyte reaction of not more than 10% that of ciclosporin
11/09/1999US5981277 Polypeptides and peptides, nucleic acids coding for them, and their use in the field of tumor therapy, inflammation or immunology
11/09/1999US5981258 Composition of trans-dominant variants of viral proteins for obtaining an antiviral effect
11/09/1999US5981196 Immunossay method
11/09/1999US5980954 Modifying the extracted blood aliquot from patient by subjecting it to an immune system-modifying amount of ozone gas and ultraviolet radiation, forming an autoimmune vaccine to treat rheumatoid arthritis
11/09/1999US5980913 A tetrapeptides as vaccine adjuvant
11/09/1999US5980899 Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells
11/09/1999US5980898 Adjuvant for transcutaneous immunization
11/09/1999US5980895 Immunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activation
11/09/1999US5980892 Increasing cytotoxicity by exposing t lymphocytes to a monoclonal antibody, reacting with an epitope of the variable region of a t cell antigen receptor; treating rheumatoid arthritis
11/09/1999US5980865 Administering to the patient of a pharmaceutical composition containing about 0.005 to about 1.0 mg of ultra-low molecular weight heparins
11/09/1999CA2106452C Amidinophenol derivatives
11/04/1999WO1999056129A1 Methods of selecting internalizing antibodies
11/04/1999WO1999055893A1 Retroviral vectors including modified envelope escort proteins
11/04/1999WO1999055873A2 Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
11/04/1999WO1999055859A2 Cd40-interacting and traf-interacting proteins
11/04/1999WO1999055734A1 A g-protein coupled 7tm receptor (axor-1)
11/04/1999WO1999055733A1 Cloning of a novel 7tm receptor axor-2
11/04/1999WO1999055715A2 Polysaccharide-antigen conjugates
11/04/1999WO1999055682A1 Methods of identifying and using hla binding compounds as hla-agonists and antagonists
11/04/1999WO1999055678A1 Quinoline derivatives
11/04/1999WO1999055663A1 Inhibitors of impdh enzyme
11/04/1999WO1999055377A2 Polyol-ifn-beta conjugates
11/04/1999WO1999055372A1 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
11/04/1999WO1999055369A1 Monoclonal antibodies with reduced immunogenicity
11/04/1999WO1999055364A2 Proteins that direct the secretion of virulence proteins and vaccines comprising them
11/04/1999WO1999055363A1 Compositions and methods for tolerization in immune complex-mediated disease progression
11/04/1999WO1999055342A1 Therapeutic anti-cold agent containing isomalt as an active ingredient
11/04/1999WO1999055330A1 Ccr-3 receptor antagonists
11/04/1999WO1999055324A1 Ccr-3 receptor antagonists
11/04/1999WO1999055321A1 Compounds and methods for treating mitochondria-associated diseases
11/04/1999WO1999055312A2 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
11/04/1999WO1999042585A9 Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
11/04/1999WO1999040921A3 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
11/04/1999WO1999033981A3 Human signal peptide-containing proteins
11/04/1999CA2565375A1 Polyol-ifn-beta conjugates
11/04/1999CA2330563A1 Therapeutic anti-cold agent containing isomalt as an active ingredient
11/04/1999CA2330458A1 Methods of identifying and using hla binding compounds as hla-agonists and antagonists
11/04/1999CA2330451A1 Polyol-ifn-beta conjugates
11/04/1999CA2330391A1 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
11/04/1999CA2329897A1 Polysaccharide-antigen conjugates
11/04/1999CA2329821A1 Ccr-3 receptor antagonists
11/04/1999CA2329777A1 Ccr-3 receptor antagonists
11/04/1999CA2329709A1 Compounds and methods for treating mitochondria-associated diseases
11/04/1999CA2327505A1 Monoclonal antibodies with reduced immunogenicity
11/04/1999CA2327504A1 Cd40-interacting and traf-interacting proteins
11/04/1999CA2326375A1 Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
11/03/1999EP0953636A2 Cytokine signal regulators
11/03/1999EP0953630A1 Transesterification products of corn oil and glycerol and their use in pharmaceutical compositions
11/03/1999EP0953351A2 Medicaments containing, as the main ingredient, allogenic activated-CD4+ cells and method for producing the same
11/03/1999EP0953049A2 Novel human metallothionein
11/03/1999EP0952974A1 Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cosmetic compositions containing same
11/03/1999EP0952846A1 Prolactin as a vaccine adjuvant
11/03/1999EP0362279B2 Saponin adjuvant
11/03/1999CN1234071A Keratinocyte grouth factor -2(KGF-2 or fibroblast growth factor-12, FGF-12)
11/03/1999CN1234038A C-end modified (N-subsd.)-2-indyldipeptide used for ICE/ced-3 family cysteine protein enzyme inhibitor
11/03/1999CN1234031A Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the prodn. of tumor necrosis factor (TNF)
11/03/1999CN1234026A Piperazino derivatives as neurokinin antagonists
11/03/1999CN1233493A Oral liquor having functions of inhibiting tumor and regulating immunization
11/02/1999US5977359 Substituted heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present
11/02/1999US5977338 Polynucleotides which hybridize with naturally occurring sequences encoding human interferon-inducible protein (hifi) and the polynucleotides which identify and encode hifi.
11/02/1999US5977336 High molecular weight surface proteins of non-typeable haemophilus
11/02/1999US5977329 Methods of synthesizing GM3
11/02/1999US5977318 The ctla4 receptor as a ligand for the b7 antigen.
11/02/1999US5977316 Antiidiotypic antibody which induces immune response to ganglioside gd2; anticarcinogenic/antitumor agents against melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma; for decreasing the risk of recurrence
11/02/1999US5977315 Murine anti-idiotype antibody 3H1
11/02/1999US5977311 53BP2 complexes
11/02/1999US5977163 Water soluble paclitaxel prodrugs
11/02/1999US5977151 Isoxazole and crotonamide derivatives and their use as pharmaceuticals and diagnostics
11/02/1999US5977122 Antiinflammatory, antiallergens, tumor necorsis factor inhibitor
11/02/1999US5977119 Trisubstituted thioxanthines
11/02/1999US5977108 Leukemia
11/02/1999US5977105 Compounds
11/02/1999US5977102 Inhibitory effect on signal transduction mediated by tyrosine kinases or epidermal growth factor; antitumor,-carcinogenic, -metastasis,-proliferation agents and -inflammatory agents; psoriasis; angiogenesis inhibitors; immunology;
11/02/1999US5977081 Triterpene saponin analogs having adjuvant and immunostimulatory activity
11/02/1999US5977067 Cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them
11/02/1999US5976877 Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
11/02/1999US5976849 Human E3 ubiquitin protein ligase
11/02/1999US5976838 Secreted proteins and polynucleotides encoding them
11/02/1999US5976834 cDNA clone HNFJD15 that encodes a novel human 7-transmembrane receptor
11/02/1999US5976831 Therapeutic compounds, and more particularly to soluble and membrane-bound forms of a low-affinity receptor for human immunoglobulin g, nucleic acids encoding the same. diagnostic uses of such receptors.
11/02/1999US5976597 Basic protein composition, basic peptide composition and application thereof
11/02/1999US5976576 Active material is n-4-(1h-tetrazol-5-yl)phenyl-4-(1h-tetrazol-5-yl)benzamide, disodium salt
11/02/1999US5976573 Aqueous-based pharmaceutical composition
11/02/1999US5976551 Altered major histocompatibility complex (MHC) determinant and method of using the determinant
11/02/1999US5976546 Antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen.
11/02/1999US5976543 12-kDa protein derived from M. Tuberculosis useful for treatment of autoimmune diseases
11/02/1999US5976539 Compositions and methods for use of IL-12 as an adjuvant
1 ... 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 ... 1172